10x Genomics (TXG) Depreciation & Amortization (CF) (2018 - 2026)

10x Genomics' Depreciation & Amortization (CF) history runs 9 years deep, the most recent figure standing at $10.0 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 24.12% year-over-year to $10.0 million; the TTM figure through Mar 2026 stood at $38.1 million (up 9.87% YoY), while the FY2025 annual figure was $36.2 million, up 0.89% from the prior year.
• Depreciation & Amortization (CF) came in at $10.0 million for Q1 2026 at 10x Genomics, down from $10.1 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $10.3 million in Q3 2025 to a low of $6.2 million in Q3 2022.
• A 5-year average of $8.4 million and a median of $9.0 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) soared 52.94% in 2023 and slipped 12.89% in 2025, its largest moves.
• 10x Genomics' Depreciation & Amortization (CF) stood at $6.5 million in 2022, then surged by 49.01% to $9.7 million in 2023, then slipped by 9.95% to $8.8 million in 2024, then increased by 15.03% to $10.1 million in 2025, then dropped by 1.07% to $10.0 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $10.0 million, $10.1 million, and $10.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison